• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ypsomed has a new CFO, board member

September 29, 2023 By Sean Whooley

Samuel Kunzli Feintool Ypsomed_waifu2x_photo_noise1_scale
Samuel Künzli

Ypsomed announced today that it selected Samuel Künzli to take over the company’s chief financial officer (CFO) position.

Niklaus Ramseier elected to hand over the reins to the CFO position after more than 20 years in the post. The transition begins on March 31, 2024, with Ramseier remaining available to the drug delivery device maker for strategic projects. Künzli begins as CFO on April 1, 2024.

Ramseier joined the Burgdorf, Switzerland-based company in 2002 as CFO. From then, he led the finance and controlling department at Ypsomed. He also took charge of the company’s IT department until midway through last year. At the end of March 2024, he departs the CFO position and his spot as a member of the executive board.

He will remain available on a reduced basis for strategic projects until his early retirement in January 2025.

Künzli spent the last three years as CFO at Feintool Group. He previously worked for Stadler for eight years in various financial management roles.

“Niklaus Ramseier has accompanied our company for more than two decades with a lot of expertise and great commitment as CFO. Thanks to his competence and reliability, we were able to master numerous challenges in the past and successfully prepare the company for the continued growth phase,” said Ypsomed CEO Simon Michel. “We thank Niklaus Ramseier for his valuable contributions to the company and are pleased that he is available to us for the further transformation.

“At the same time, I am pleased that we were able to win Samuel Künzli, a proven financial expert with capital market experience, as his successor. I am convinced that Samuel Künzli will optimally support the execution of our strategy. We give him a warm welcome.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel Tagged With: Personnel Moves, Ypsomed

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS